1. Department of Epidemiology and Technology Assessment, University of Maastricht, Maastricht, The Netherlands;
2. Bayer AG, Leverkusen, Germany;
3. Department of Cardiothoracic and Vascular Sciences, Vascular Medicine Unit, University of Padua, Padua, Italy;
4. Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, Canada;
5. Vascular Medicine and Hemostasis, University of Leuven, Leuven, Belgium;
6. Department of Hematology, Medical Clinic I, University Hospital Carl Gustav Carus, Dresden, Germany;
7. Department of Haematology and Oncology, King’s College, London, United Kingdom;
8. Vascular Medicine, Klinikum Darmstadt, Darmstadt, Germany;
9. Center for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany;
10. Division of Angiology and Hemostasis, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland;
11. Department of Haematology, Prince of Wales Hospital, Sydney, Australia;
12. Department of Haematological Medicine, Guy’s and St. Thomas’ Hospitals, London, United Kingdom;
13. University of Washington School of Medicine, Seattle, WA;
14. Centre d’Investigation Clinique 1408, Sainbiose U1059, Investigation Network On Venous Thromboembolism, Service de Médecine Vasculaire et Thérapeutique, Centre Hospitalo-Universitaire, Hôpital Nord, Saint Etienne, France;
15. Thrombosis Research Institute and University College London, London, United Kingdom;
16. Hospital Beneficência Portuguesa, São Paulo, Brazil; and
17. Thrombosis and Atherosclerosis Research Institute and McMaster University, Hamilton, ON, Canada